A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2004
11/25/2004	WO2004100997A2 Spacer moiety for poly(ethylene glycol) -modified peptides
11/25/2004	WO2004100995A1 Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
11/25/2004	WO2004100994A2 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
11/25/2004	WO2004100993A1 Composition for ophthalmic use
11/25/2004	WO2004100983A2 Treatment of lupus targeting the macrophages or the folate receptor
11/25/2004	WO2004100979A2 Liquid stabilized protein formulations in coated pharmaceutical containers
11/25/2004	WO2004100965A1 Immunostimulant
11/25/2004	WO2004100935A2 Propofol formulation containing reduced oil and surfactants
11/25/2004	WO2004100926A2 Delivery of agents using hydrolyzable leaving groups
11/25/2004	WO2004100866A2 Alcohol-free transdermal analgesic composition
11/25/2004	WO2004100826A2 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
11/25/2004	WO2004082607A3 A method of preparing gas-filled polymer matrix microparticles useful for delivering drug
11/25/2004	WO2004081056A3 Controlled release polymeric gels
11/25/2004	WO2004069204A3 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
11/25/2004	WO2004061458A3 Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
11/25/2004	WO2004060378A3 Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof
11/25/2004	WO2004004683A8 Solid dispersions comprising two different polymer matrixes
11/25/2004	WO2003103718A3 Intracellular delivery of biological effectors
11/25/2004	WO2003086280A3 Immunostimulatory g,u-containing oligoribonucleotides
11/25/2004	WO2003050260A3 Streptavidin expressed gene fusions and methods of use thereof
11/25/2004	WO2003000006A3 Stackable low depth tray
11/25/2004	US20040236098 Tocopheryl retinyl succinate, tocopheryl cholecalciferyl succinate or tocopheryl ascorbyl succinate; sustained releasing active agents or vitamin by hydrolyzing with esterase contained in the skin; dermatology, cosmetics
11/25/2004	US20040236097 Branched cyclic tetrasaccharide, process for producing the same, and use
11/25/2004	US20040236096 Peptide deformylase activated prodrugs
11/25/2004	US20040236095 formed by readcting chitosan with iminothiolane; improved viscoelasticity and gelation; for use in hair gels, eye drops, stents, and tissue engineering
11/25/2004	US20040236076 Polyclonal IgY compound from eggs of transgenic SPF-chickens with constant regions of human IgG and additionally consist of at least one signal and/or active agent and/or booster molecule; for treating noninfectious inflammations, infectious diseases, clotting disorders, autoimmune diseases and cancer
11/25/2004	US20040236015 Segmented polymers and their conjugates
11/25/2004	US20040235964 Stable clear solution of sterile propofol solution in water
11/25/2004	US20040235962 Conformationally restricted polyamine analogs as disease therapies
11/25/2004	US20040235935 A statin derivative suspended in at least an oily excipient: for releasing water free suspension in gastrointestinal system
11/25/2004	US20040235917 Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans
11/25/2004	US20040235885 Novel composition and method for stabilizing the same
11/25/2004	US20040235840 For therapy of tumors
11/25/2004	US20040235803 Dispersible formulation of an anti-inflammatory agent
11/25/2004	US20040235795 Administration of an agent produced from phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof in combination with additive selected from a group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters, phospholipids
11/25/2004	US20040235759 Increasing acute or chronic injection-site toleration in mammals by administering single dose descladinose azalide derivative mixture
11/25/2004	US20040235758 Foods; skin, lipid, liver, and cardiovascular disorders; hormone dependent diseases, osteopenia, osteoporosis,and acute ovarian estrogen deficiency; biosynthesis by metabolism of isoflavone; drug delivery
11/25/2004	US20040235746 Cell permeable peptides for inhibition of inflammatory reactions and methods of use
11/25/2004	US20040235734 Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor
11/25/2004	US20040235731 package contains low molecular weight peptide-based thrombin inhibitors (melagatran), sealed with rubber stopper/plunger
11/25/2004	US20040235729 Complementarity-determining region; monoclonal antibodies; antiidiotypic antibodies; autoantibodies; heavy chains; light chains; polypeptides; amino acid sequences; DNA; carriers; use for treatment of systemic lupus erythematosus in humans
11/25/2004	US20040235727 Comprising H 376/95, sodium dodecyl sulphate, and a polymer selected from hydroxypropyl methylcellulose, hydroxyethyl cellulose, and polyoxyethylene oxide; use in treatment of thromboembolism
11/25/2004	US20040235719 Reacting a first aliquot of the protein with a heterobifunctional coupling agent; and reacting the product with a second aliquot of the protein wherein the coupling reagent contains groups reactive to thiol groups and groups reactive to amine groups
11/25/2004	US20040235712 Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
11/25/2004	US20040235708 Method for preventing the formation of adhesions following surgery or injury
11/25/2004	US20040235091 Preparing protease resistant, bioactive amino acid sequences for use as therapeutic peptides; biodrugs; mimetics
11/25/2004	US20040235065 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
11/25/2004	US20040235016 Solid support comprising nanotubes and/or nanorods for use in electronic devices, field emission sources and chemical sensors; semiconductors
11/25/2004	US20040234916 Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
11/25/2004	US20040234914 Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
11/25/2004	US20040234699 Coating a layer of solid fuel capable of undergoing exothermic metal oxidation reaction to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon
11/25/2004	US20040234676 contacting a gas with a fluid comprising cellulose ether, cellulose ester, polyalkylene oxide, or homo- or copolymer of vinyl alcohol or vinylpyrrolidone, and a liquid diluent, preferably water, to produce a foam, and contacting the foam with solid particles and agitating
11/25/2004	US20040234633 Composition containing horse chestnut extract
11/25/2004	US20040234616 Long acting injectable insulin composition and methods of making and using thereof
11/25/2004	US20040234615 Oral insulin composition and methods of making and using thereof
11/25/2004	US20040234614 Chitin microparticles and their medical uses
11/25/2004	US20040234611 Active material embedded into biocompatible polymer or lipid
11/25/2004	US20040234609 Repeat sequence protein polymer active agent congjugates, methods and uses
11/25/2004	US20040234606 Localized vaginal delivery without detrimental blood levels
11/25/2004	US20040234601 Absorption in upper part oof digestive system; oral administering
11/25/2004	US20040234594 Inhibiting gastric acid secretory; antiulcer agent; oral dosage form
11/25/2004	US20040234592 Mixture containing thyroid hormone , ethanolamine and emulsifier
11/25/2004	US20040234590 Film forming envelope encloding core; food, drugs, oral hygiene, cosmetics
11/25/2004	US20040234589 Mixture with carrier; storage stability packaging; freeze drying
11/25/2004	US20040234586 Compositions and methods for enhancing nucleic acid transfer into cells
11/25/2004	US20040234584 Transdermal therapeutic system with fentanyl or related substances
11/25/2004	US20040234583 Transdermal therapeutic system (tts) with fentanyl as a active ingredient
11/25/2004	US20040234578 Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
11/25/2004	US20040234572 Preparation of sustained release pharmaceutical composition
11/25/2004	US20040234563 Emulsifier mixture
11/25/2004	US20040234556 Aerosol mixture of drug particles in fluorohydrocarbon propellant
11/25/2004	US20040234544 Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
11/25/2004	US20040234533 Antigenic compositions
11/25/2004	US20040234527 Peptides for use as translocation factors
11/25/2004	US20040234521 Antigen detection segments; crosslinking receptors
11/25/2004	US20040234497 complexing hyaluronic acidand cell surface receptor overexpression on cancer cell surfaces
11/25/2004	US20040234495 Antitumor agents and process for producing the same
11/25/2004	US20040234494 biocompatible , biodegradation ; increase drug concentration; stability
11/25/2004	US20040234474 mixture of silicone fluid , silica and drug; wound dressing; topical applying; drug delivery
11/25/2004	US20040234472 Micellar drug delivery systems for hydrophobic drugs
11/25/2004	DE20220982U1 Transdermal patch, useful for administering fentanyl or its analog through the skin, comprises a backing layer on which a reservoir containing a single phase polymeric composition is disposed
11/25/2004	DE10362021A1 Improving the flow of body fluids, e.g. lymph, blood and tissue fluids, comprises introducing an antifoam into the bloodstream in the lymphatic system
11/25/2004	CA2566874A1 Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
11/25/2004	CA2527756A1 Immunostimulating agents
11/25/2004	CA2526025A1 Preventive and/or remedy for diseases accompanied by tissue destruction
11/25/2004	CA2525899A1 Ovr110 antibody compositions and methods of use
11/25/2004	CA2525464A1 Novel poly(ethylene glycol) modified compounds and uses thereof
11/25/2004	CA2525396A1 Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
11/25/2004	CA2524816A1 Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
11/25/2004	CA2524097A1 Alcohol-free transdermal analgesic composition
11/25/2004	CA2523477A1 Stabilized liquid protein formulations in pharmaceutical containers
11/25/2004	CA2523045A1 Anti-inflammatory phosphonate compounds
11/25/2004	CA2522765A1 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
11/25/2004	CA2522690A1 Inhibition of drug binding to serum albumin
11/24/2004	EP1479711A1 Multidrop tree branching functional polyethylene glycol, the preparation method and the use of it
11/24/2004	EP1479393A1 Stabilized albumin preparations
11/24/2004	EP1479389A1 Ready to use gemcitabine solutions
11/24/2004	EP1479388A1 Ready to use gemcitabin solution concentrates
11/24/2004	EP1479379A1 Dry liposomal PVP-iodine compositions
11/24/2004	EP1478927A2 Macromolecular conjugates and processes for preparing same

1 ... 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 ... 1712